LAVA Therapeutics Future Growth
Future criteria checks 2/6
LAVA Therapeutics's earnings are forecast to decline at 21.4% per annum while its annual revenue is expected to grow at 50.3% per year. EPS is expected to decline by 8.5% per annum.
Key information
-21.4%
Earnings growth rate
-8.5%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 50.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 12 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -78 | -62 | N/A | 3 |
| 12/31/2025 | N/A | -59 | -35 | N/A | 3 |
| 12/31/2024 | 5 | -34 | -26 | N/A | 3 |
| 6/30/2024 | 7 | -24 | -27 | -27 | N/A |
| 3/31/2024 | 13 | -29 | -32 | -32 | N/A |
| 12/31/2023 | 7 | -42 | -40 | -39 | N/A |
| 9/30/2023 | 9 | -50 | 6 | 7 | N/A |
| 6/30/2023 | 24 | -41 | -1 | 0 | N/A |
| 3/31/2023 | 20 | -36 | 3 | 3 | N/A |
| 12/31/2022 | 19 | -32 | 3 | 4 | N/A |
| 9/30/2022 | 18 | -25 | -40 | -39 | N/A |
| 6/30/2022 | 5 | -33 | -34 | -33 | N/A |
| 3/31/2022 | 5 | -32 | -33 | -32 | N/A |
| 12/31/2021 | 5 | -42 | -29 | -29 | N/A |
| 9/30/2021 | 6 | -37 | -29 | -28 | N/A |
| 6/30/2021 | 5 | -34 | -25 | -24 | N/A |
| 3/31/2021 | 5 | -31 | -12 | -11 | N/A |
| 12/31/2020 | 4 | -16 | -10 | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4PKB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 4PKB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 4PKB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 4PKB's revenue (50.3% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 4PKB's revenue (50.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 4PKB's Return on Equity is forecast to be high in 3 years time